Safety and Tolerability of Yaq-001 in Patients With Cirrhosis

Stopped COVID-19 pandemic prevents patients from making in-hospital visits, which are mandatory to assessment of safety in this study

Conditions

• Liver Cirrhosis

Interventions

• DEVICE: 4g Yaq-001
• OTHER: 4g Placebo
• DEVICE: 8g Yaq-001
• OTHER: 8g Placebo

Sponsor

Yaqrit Ltd

Collaborators

• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]